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Background: Gemcitabine is a standard treatment for pancreatic adenocarcinoma.
Many mechanisms are involved in gemcitabine resistance, such as reduced expression
of the human equilibrative nucleoside transporter 1 (hENT1) membrane transporter,
deoxycytidine kinase deficiency, and changes in the signal transmission of mitogen-
activity protein kinase (MAPK) and the phosphoinositide 3-kinase (PI3K) pathways.
Aim: To evaluate the anti-tumor efficiency of blocking signaling pathways using
combined action of gemcitabine, everolimus and zoledronic acid versus gemcitabine
alone in a mouse subcutaneous xenograft.
Methods: Implantations of two human pancreatic adenocarcinoma cells lines (PANC1,
K-ras mutated and gemcitabine-resistant; and BxPc3, wild-type K-ras and gemcitabine-
sensitive) were performed on male athymic nude mice. The mice received different
treatments: gemcitabine, gemcitabine plus everolimus, everolimus, gemcitabine plus
zoledronic acid, everolimus plus zoledronic acid, or gemcitabine plus everolimus and
zoledronic acid, for 28 days. We measured the tumor volume and researched the
expression of the biomarkers involved in the signaling pathways or in gemcitabine
resistance.
Results: In wild-type K-ras tumors, the combinations of gemcitabine plus everolimus;
zoledronic acid plus everolimus; and gemcitabine plus zoledronic acid and everolimus
slowed tumor growth, probably due to caspase-3 overexpression and reduced Annexin
II expression. In mutated K-ras tumors, gemcitabine plus everolimus and zoledronic
acid, and the combination of zoledronic acid and everolimus, decreased tumor volume
as compared to gemcitabine alone, inhibiting the ERK feedback loop induced by
everolimus.
Conclusion: The combination of zoledronic acid and everolimus has an antitumor effect
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